Tags
"mild myocarditis", all health outcomes ignored, children 5 to 11, compromising natural immunity, deliberately underpowered trials, insufficient follow up time period, no demonstrated benefit, no emergency among children, red flags, skewed safety follow up after Dose 2, the FDA's risk-benefit analysis, wiped out control group
Hat tip: Steve Kirsch
Source: uTobian
Ten red flags in the FDA’s risk-benefit analysis of Pfizer’s EUA application to inject American children 5 to 11 with its mRNA product
The FDA briefing document is preposterous junk science and it must be withdrawn immediately
| By Toby Rogers |
Where to even begin with the FDA’s preposterous risk-benefit analysis of Pfizer’s mRNA COVID-19 “vaccine” in children ages 5 to 11?
Let’s start with my bona fides. I have a year of undergraduate statistics at one of the best liberal arts colleges in America (Swarthmore). I have a year of graduate statistics at the masters program rated #1 for policy analysis (UC Berkeley). And I have a Ph.D. in political economy from one of the top universities in the world (University of Sydney). My research focus is on corruption in the pharmaceutical industry so I’ve read scientific studies in connection with vaccines nearly every day for 5 years. Earlier in my career I worked professionally tearing apart shoddy cost-benefit analyses prepared by corporations that were trying to get tax breaks, contracts, and other concessions from local government. Suffice it to say I’ve thought a lot about risk-benefit analysis and I’m better equipped than most to read one of these documents.
The FDA’s risk-benefit analysis in connection with Pfizer’s Emergency Use Authorization (EUA) application to inject children ages 5 to 11 with their COVID-19 vaccine is one of the shoddiest documents I’ve ever seen.
Let’s take it from the top:
Continue reading ======>uTobian<======
Taking Sides 